...
search icon
gtbp-img

GT Biopharma Inc, Common Stock

GTBP

NAQ

$3.055

+$0.04

(1.32%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$7.01M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
44.75K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.39
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.72 L
$4.1 H
$3.055

About GT Biopharma Inc, Common Stock

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms. It develops GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550 that targets B7-H3 on the surface of advanced solid tumors; and GTB-7550, a product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameGTBPSectorS&P500
1-Week Return11.44%1.08%1.16%
1-Month Return33.04%1.11%6.29%
3-Month Return21.29%-9.16%6.93%
6-Month Return12.54%-7.29%-0.84%
1-Year Return5.96%-8.72%11.95%
3-Year Return-96.72%5.18%49.35%
5-Year Return-97.31%30.45%86.83%
10-Year Return-100%81.41%188.52%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses6.76M57.52M21.26M13.58M14.36M[{"date":"2020-12-31","value":11.76,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":36.96,"profit":true},{"date":"2023-12-31","value":23.6,"profit":true},{"date":"2024-12-31","value":24.97,"profit":true}]
Operating Income(6.76M)(57.52M)(21.26M)(13.58M)(14.36M)[{"date":"2020-12-31","value":-676400000,"profit":false},{"date":"2021-12-31","value":-5751500000,"profit":false},{"date":"2022-12-31","value":-2125700000,"profit":false},{"date":"2023-12-31","value":-1357600000,"profit":false},{"date":"2024-12-31","value":-1436400000,"profit":false}]
Total Non-Operating Income/Expense(24.85M)(1.18M)657.00K6.50M1.60M[{"date":"2020-12-31","value":-382.4,"profit":false},{"date":"2021-12-31","value":-18.13,"profit":false},{"date":"2022-12-31","value":10.11,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":24.68,"profit":true}]
Pre-Tax Income(28.30M)(58.01M)(20.88M)(7.60M)(13.16M)[{"date":"2020-12-31","value":-2829600000,"profit":false},{"date":"2021-12-31","value":-5801300000,"profit":false},{"date":"2022-12-31","value":-2088400000,"profit":false},{"date":"2023-12-31","value":-759700000,"profit":false},{"date":"2024-12-31","value":-1316200000,"profit":false}]
Income Taxes3.32M680.00K(381.00K)(13.58K)-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":20.48,"profit":true},{"date":"2022-12-31","value":-11.48,"profit":false},{"date":"2023-12-31","value":-0.41,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(31.62M)(58.69M)(20.50M)(7.58M)-[{"date":"2020-12-31","value":-3161600000,"profit":false},{"date":"2021-12-31","value":-5869300000,"profit":false},{"date":"2022-12-31","value":-2050300000,"profit":false},{"date":"2023-12-31","value":-758342400,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(28.30M)(58.01M)(20.88M)(10.22M)(13.16M)[{"date":"2020-12-31","value":-2829600000,"profit":false},{"date":"2021-12-31","value":-5801300000,"profit":false},{"date":"2022-12-31","value":-2088400000,"profit":false},{"date":"2023-12-31","value":-1021900000,"profit":false},{"date":"2024-12-31","value":-1316200000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(31.62M)(58.69M)(20.50M)(7.60M)(13.16M)[{"date":"2020-12-31","value":-3161600000,"profit":false},{"date":"2021-12-31","value":-5869300000,"profit":false},{"date":"2022-12-31","value":-2050300000,"profit":false},{"date":"2023-12-31","value":-759700000,"profit":false},{"date":"2024-12-31","value":-1316200000,"profit":false}]
EPS (Diluted)(3.57)(4.23)(0.67)(2.31)(7.02)[{"date":"2020-12-31","value":-357,"profit":false},{"date":"2021-12-31","value":-423,"profit":false},{"date":"2022-12-31","value":-67,"profit":false},{"date":"2023-12-31","value":-231,"profit":false},{"date":"2024-12-31","value":-702.32,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

GTBP
Cash Ratio 0.65
Current Ratio 0.73

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

GTBP
ROA (LTM) -131.32%
ROE (LTM) -538.87%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

GTBP
Debt Ratio Lower is generally better. Negative is bad. 1.37
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.37

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

GTBP
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 2.54
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is GT Biopharma Inc share price today?

GT Biopharma Inc (GTBP) share price today is $3.055

Can Indians buy GT Biopharma Inc shares?

Yes, Indians can buy shares of GT Biopharma Inc (GTBP) on Vested. To buy GT Biopharma Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GTBP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of GT Biopharma Inc be purchased?

Yes, you can purchase fractional shares of GT Biopharma Inc (GTBP) via the Vested app. You can start investing in GT Biopharma Inc (GTBP) with a minimum investment of $1.

How to invest in GT Biopharma Inc shares from India?

You can invest in shares of GT Biopharma Inc (GTBP) via Vested in three simple steps:

  • Click on Sign Up or Invest in GTBP stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in GT Biopharma Inc shares
What is GT Biopharma Inc 52-week high and low stock price?

The 52-week high price of GT Biopharma Inc (GTBP) is $4.1. The 52-week low price of GT Biopharma Inc (GTBP) is $1.72.

What is GT Biopharma Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of GT Biopharma Inc (GTBP) is 2.54

What is the Market Cap of GT Biopharma Inc?

The market capitalization of GT Biopharma Inc (GTBP) is $7.01M

What is GT Biopharma Inc’s stock symbol?

The stock symbol (or ticker) of GT Biopharma Inc is GTBP

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top